The goals of the development of the pharmaceutical and vaccine industry, as based on the BCG concept, cover four areas: (1) vaccines, (2) drugs, active pharmaceutical ingredients (API), and biomaterials, (3) advanced therapy, and (4) genomics and precision medicine. There are three criteria for selecting target branches:
1. It is a product with high impact on industry and medical services (generating revenue, building self-sufficiency for the country) and essential for the health service system of the Thai people;
2. The country is well-prepared (key players, infrastructure, and natural resources);
3. It has a high chance of success within 3-5 years, considering gap analysis results based on market status and BCG developments.
When analyzed in conjunction with technological capabilities, the development goals of the industries related to pharmaceuticals and vaccines can be described in the following way: “Increasing self-reliance capabilities, expanding service business bases, and increasing export capabilities of health and medical products through research and development of technology and innovation based on the concept of business promotion operated by Thai private sectors in order to create competitiveness on par with large multinational businesses, create economic growth, and become a production base in emergency and necessary situations of the country.”
The implementation of these goals will increase the country's GDP from 40,000 million baht to 90,000 million baht by 2024, reduce the burden of medical and public health expenses of the country, reduce the import of medicines and vaccines by not less than 7,500 million baht per year, and reduce inequality in access to expensive medicines and vaccines for more than 300,000 people, leading to health security in all situations, during both normal and pandemic times.
Source: National Science and Technology Development Agency (NSTDA)
Tel: +66 2 564 8000
EN
CN
DE
JP
TH
